AsianScientist (Sep. 18, 2015) – Takeda Pharmaceutical Company Limited has joined the World Intellectual Property Organization (WIPO) Re:Search, a consortium to accelerate research and development (R&D) of new drugs, vaccines, and diagnostics for neglected tropical diseases such as malaria and tuberculosis (TB). WIPO Re:Search’s aim is to advance product development through greater collaboration while making concrete contributions to strengthen the foundations of healthcare in developing countries.
“Takeda’s participation in the consortium demonstrates our commitment to supporting better access to medicines for people around the world, including those in emerging markets and developing counties,” said Isabel Torres, Director, Access to Medicines, Takeda.
WIPO Re:Search was established in 2011 by the WIPO in collaboration with BIO Ventures for Global Health (BVGH) and with the active participation of leading pharmaceutical companies and other renowned public sector research organizations. Through a public database managed by WIPO, members of the consortium, including the US National Institutes of Health (NIH), provide their intellectual property assets and resources such as compounds, expertise, know-how, etc., under royalty-free licenses.
Non-profit organizations and other qualified research institutions will gain access to these assets for the research and development of new drugs, vaccines, and diagnostics. By sharing assets and relevant information via the database, the consortium promotes research to develop innovative treatments for patients.
Based on the needs of WIPO Re:Search members, Takeda and BVGH are currently working together to evaluate and determine potential assets and future contributions from Takeda to the consortium.
———
Source: Takeda.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
